Trial Profile
Cardio-Protective of Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients With Type 2 Diabetes
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Dapagliflozin/saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 26 Jun 2023 Results assessing whether Dapa will improve the outcomes when compared to placebo and the Combo , presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 07 Nov 2022 Results assessing Dapa will improve EPC number and function compared to placebo and combo may have additional positive effects presented at the American Heart Association Scientific Sessions 2022
- 21 Mar 2022 Status changed from recruiting to discontinued.